Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease.

Date publication

octobre 2017

Journal

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Lindsay JO, Armuzzi A, Gisbert JP, Bokemeyer B, Peyrin-Biroulet L, Nguyen GC, Smyth M, Patel H

Lien Pubmed

http://www.ncbi.nlm.nih.gov/pubmed/28826571

Résumé

Inflammatory bowel disease (IBD) is refractory to treatment in one-half of patients.

Mots clés

Chart review, Crohn’s disease, Inflammatory bowel disease, Suboptimal therapy, Tumor necrosis factor-alpha (TNF-α) antagonists, Ulcerative colitis

Référence

Dig Liver Dis. 2017 Oct;49(10):1086-1091